(Q37523898)

20 August 2017

1 reference

title

Clinical biomarkers in oncology: focus on colorectal cancer (English)

1 reference

20 August 2017

0 references

1 reference

4

Sabine Tejpar

0 references

author name string

Wendy De Roock

series ordinal

1

1 reference

20 August 2017

Bart Biesmans

series ordinal

2

1 reference

20 August 2017

Jef De Schutter

series ordinal

3

1 reference

20 August 2017

publication date

1 January 2009

1 reference

Molecular Diagnosis and Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

13

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

103-114

1 reference

Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Reporting recommendations for tumor marker prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

A genetic model for colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Colorectal cancer and genetic alterations in the Wnt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Genetic instabilities in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Role of DNA mismatch repair defects in the pathogenesis of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Systematic review of microsatellite instability and colorectal cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Molecular staging for survival prediction of colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Metabolism and mechanism of action of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Role of genomic markers in colorectal cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

p53 mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

The epidermal growth factor receptor pathway: a model for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

SMAD4 as a Prognostic Marker in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256319

Allelic loss of chromosome 18q and prognosis in colorectal cancer

21 January 2018

1 reference

12 December 2020

Cancer as a robust system: implications for anticancer therapy

1 reference

12 December 2020

Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival

1 reference

12 December 2020

Don Quixote and the quest for personalized medicine

1 reference

12 December 2020

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

Stage II colon cancer prognosis prediction by tumor gene expression profiling

1 reference

12 December 2020

Tumor markers: from laboratory to clinical utility

1 reference

12 December 2020

p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma

1 reference

12 December 2020

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

1 reference

12 December 2020

Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study

1 reference

12 December 2020

Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.

1 reference

12 December 2020

Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs

1 reference

12 December 2020

Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil

1 reference

12 December 2020

Determinants of RASistance to anti-epidermal growth factor receptor agents

1 reference

12 December 2020

Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.

1 reference

12 December 2020

Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256319

1 reference

20 August 2017

1 reference